The original disclosure in Japanese was released on November 1, 2013 at 16:00 (GMT+9)

Consolidated Financial Statements for the Second Quarter Ended September 30, 2013 FY2014 (April 1, 2013 - March 31, 2014) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): November 8, 2013

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the six months ended September 30, 2013 (April 1, 2013 – September 30, 2013)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Six months ended September 30, 2013		Six months ended September 30, 2012	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	97,561	1.9	95,711	0.2
Operating income	2,395	(17.4)	2,899	(12.8)
Ordinary income	2,564	(10.8)	2,874	(16.7)
Net income	6,609	-	405	(57.7)
Net income per share (Yen)	32.58		1.98	
Fully diluted net income per share (Yen)	32.58		-	
Note: Comprehensive income	17,559	-	241	(62.8)

(2) Financial position

	As of September 30, 2013	As of March 31, 2013
	(Millions of yen)	(Millions of yen)
Total assets	233,157	207,586
Net assets	138,609	114,318
Equity ratio (%)	49.3	48.2
(Reference) Equity	114,914	100,040

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2013	Year ending March 31, 2014	Year ending March 31, 2014 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-		-
Year end	9.00		9.00
Annual	9.00		9.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2014 (April 1, 2013 – March 31, 2014)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2014	
	(Millions of yen)	(%)
Net sales	209,000	4.0
Operating income	9,300	1.8
Ordinary income	9,600	3.3
Net income	9,700	106.9
Net income per share (Yen)	47.82	

Note: Correction of financial forecast from the most recent financial forecast : Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change is subsidiaries) : No

(2) Applying of specific accounting of the consolidated quarterly financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard : No
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of September 30, 2013 :	217,699,743
As of March 31, 2013 :	217,699,743

2) Number of treasury stocks at year end

As of September 30, 2013 :	14,850,750
As of March 31, 2013 :	14,833,716

3) Average number of outstanding shares

Six months ended September 30, 2013 :	202,857,741
Six months ended September 30, 2012 :	204,617,043

Contents of the attached document

1. Qualitative Information for the Six Months Ended September 30, 2013 ---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 4
2. Consolidated Quarterly Financial Statements ---------- 5
   (1) Consolidated Quarterly Balance Sheets ---------- 5
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ---------- 7
   Consolidated Quarterly Statements of Income
   (For the Six Months Ended September 30, 2013 and 2012) ---------- 7
   Consolidated Quarterly Statements of Comprehensive Income
   (For the Six Months Ended September 30, 2013 and 2012) ---------- 8
   (3) Consolidated Quarterly Statements of Cash Flows ---------- 9
   (4) Notes on Consolidated Quarterly Financial Statements ---------- 10
   (Notes on Premise of Going Concern) ---------- 10
   (Notes on Material Changes in Shareholders' Equity) ---------- 10
   (Segment Information) ---------- 10

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Six Months Ended September 30, 2013

(1) Consolidated Financial Results

In the six months ended September 30, 2013, the Japanese economy saw recovery in consumer confidence stemming from the influences of yen depreciation and rising stock prices. In addition, performance of companies improved, particularly for exporters, and there was recovery in capital investment. These factors created a gradual recovery trend in the domestic economy. Nevertheless, there was cause for concern including economic slowdown in emerging countries, higher prices for general consumer goods resulted from the rise in prices for imported raw materials that accompanied yen depreciation, and projected demand trends before and after the scheduled consumption tax hike in Japan. Accordingly, the operating environment remains opaque.

In this environment, we endeavored to improve corporate value through the establishment of a balanced organizational structure that is resilient to changes in the environment by acting in accordance with the Takara Group Medium-Term Management Plan FY2014, which has "aiming to realize the Takara Group Vision2020, achieve stable growth in Japan while expanding business base in order to grow significantly overseas" as its basic policy. The Takara Group Vision 2020 embodies our long-term management vision.

In the domestic alcoholic beverages business, the Group focused its resources on developing original new products and cultivating brands in response to diversifying customer preferences. In the seasonings and raw alcohol business, the Group made concerted efforts to increase sales by proposing differentiated products that meet customer needs.

In the overseas alcoholic beverages business and the Japanese food ingredients wholesale business, the Group worked to accelerate business expansion by spreading Japanese food culture across the globe. In addition, management rights in Tazaki Foods Limited, which conducts a Japanese food ingredient wholesale business in the United Kingdom, were acquired in September 2013.

In the Biomedical business, management resources were focused on three areas—the genetic engineering research business, the gene medicine business, and the agribio business—in pursuit of improved performance.

In the six months ended September 30, 2013, net sales edged up 1.9% year on year, to ¥97,561 million, as a result of the increase in sales of overseas subsidiaries stemming from yen depreciation among other factors. Gross profit increased 1.1%, to ¥36,953 million, due to the higher net sales.

Selling, general and administrative (SG&A) expenses were up 2.7% year on year, to ¥34,558 million, following a rise in personnel expenses among other factors. Consequently, operating income decreased 17.4%, to ¥2,395 million. In regard to non-operating income and expenses, stock issuance cost was recorded in conjunction with the issuance of new shares by Takara Bio Inc., through a public stock offer. However, this was offset by the fact that the foreign exchange losses recorded in the six months ended September 30, 2012, were replaced with foreign exchange gains and the bond issuance cost recorded in the previous corresponding period was not recorded in the period under review. These factors resulted in a slight improvement in the balance of non-operating items. Nevertheless, ordinary income decreased 10.8%, to ¥2,564 million.

In regard to extraordinary income and loss, extraordinary income was recorded from the sale of a portion of the stock held by the Company in Takara Bio, which was conducted in conjunction with the issuance of new shares by this company through a public stock offer. Coupled with the absence of the loss on valuation of investment securities recorded in the six months ended September 30, 2012, this resulted in a significant improvement in the balance of these items. As a result, income before income taxes and minority interests showed a substantial increase of 636.6% year on year, to ¥11,839 million, and net income jumped 1,529.7%, to ¥6,609 million.

Results by business segment were as follows.

[Takara Shuzo Group]

In the six months ended September 30, 2013, net sales for the Takara Shuzo Group rose by a slight 0.9% year on year, to ¥85,712 million.

By product category, overall sales of mainstay shochu products decreased substantially following sluggish sales of all products, particularly standard ko-type shochu. Conversely, sales of sparkling sake Sho-Chiku-Bai Shirakabe-gura Mio were up due to the expansion of sales channels, which resulted in higher overall sales of sake. In light-alcohol refreshers, Takara Shochu High Ball maintained its popularity and contributions from new products led to sales increases. Sales of whisky by overseas subsidiaries were also strong thanks to the influences of yen depreciation among other factors. However, the decline in shochu sales weighed heavily, and overall sales of alcoholic beverages decreased as a result. In the other category, the Japanese food ingredients wholesale business experienced significant sales increases in foreign currency, which were further amplified by the influences of yen depreciation.

Cost of sales was up 1.8% year on year, to ¥55,239 million, due to rising raw material prices and a higher cost of sales ratio following changes in product mixes. As a result, gross profit was down 0.5%, to ¥30,473 million. SG&A expenses increased 1.4%, to ¥29,009 million, due to higher transportation costs and personnel expenses among other factors, and operating income for the Takara Shuzo Group declined 27.3%, to ¥1,463 million, accordingly.

[Takara Bio Group]
In the six months ended September 30, 2013, net sales for the Takara Bio Group increased 14.0% year on year, to ¥10,277 million, as a result of increases in sales of research reagents in the genetic engineering research business and the strong performance of the gene medicine business. Cost of sales was up 18.0%, to ¥4,673 million, due to differences between the cost of sales ratios of individual products. Regardless, gross profit increased 10.9%, to ¥5,603 million. Higher personnel expenses, R&D expenses, and other factors led to an 11.2% increase in SG&A expenses, to ¥5,148 million, but operating income rose 7.3%, to ¥454 million, regardless.

[Takara Healthcare]
In the six months ended September 30, 2013, net sales for Takara Healthcare took a substantial drop of 40.6% year on year, to ¥674 million, due to the end of the tea beverages PB supply business. In health care business, net sales rose 10.8% when the tea beverages PB supply business is excluded from consideration. This was because sales were up for mainstay fucoidian-related products and sales of other products were favorable. Gross profit declined in conjunction with the end of the tea beverages PB supply business, and, while we worked to reduce SG&A expenses, operating loss was relatively unchanged year on year at ¥4 million.

[Other]
Net sales of business segments other than the reported segments decreased 3.9% year on year, to ¥3,477 million, but operating income was up 94.0%, to ¥103 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2012, to September 30, 2012)	Period under Review (from April 1, 2013, to September 30, 2013)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	35,886	33,128	92.3
Sake	7,903	8,368	105.9
Light-alcohol refreshers	13,394	14,467	108.0
Other alcoholic beverages	5,415	5,986	110.5
Alcoholic beverages total	62,599	61,950	99.0
Hon Mirin	6,928	6,811	98.3
Other seasonings	3,676	3,940	107.2
Seasonings total	10,605	10,751	101.4
Raw alcohol, etc.	3,223	3,184	98.8
Transportation	5,385	5,692	105.7
Other	3,094	4,131	133.5
Total	84,909	85,712	100.9
Takara Bio Group	9,013	10,277	114.0
Takara Healthcare	1,135	674	59.4
Other	3,617	3,477	96.1
Sales not allocated to business segments and intersegment transactions	(2,964)	(2,579)	-
Total	**95,711**	**97,561**	**101.9**

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position
Total assets stood at ¥233,157 million as of September 30, 2013, up ¥25,571 million from March 31, 2013, the end of the previous fiscal year. Current assets increased ¥13,792 million, to ¥147,077 million, due to factors including a rise in securities, a measure for temporarily managing the revenues resulted from the issuance of new shares by Takara Bio through a public stock offer and the sale of a portion of this company's stock held by the Company, as a well as an increase in inventories. Noncurrent assets increased ¥11,778 million, to ¥86,079 million, following an increase in goodwill associated with the acquisition of new subsidiaries as well as a rise in investment securities, a measure to manage revenues from the issuance of new stock.

Total liabilities amounted to ¥94,547 million as of September 30, 2013, up ¥1,279 million from March 31, 2013. This was because of increases in income taxes payable, resulted from the recording of gain on sales of subsidiaries and affiliates' stocks, and in noncurrent assets-other, which offset the decrease resulted from the redemption of current portion of bonds.

Total net assets were ¥138,609 million as of September 30, 2013, up ¥24,291 million from March 31, 2013, due

a rise in minority interests and significantly higher retained earnings, which was the result of the change in equity in Takara Bio following its issuance of new shares through a public stock offer and the recording of gain on sales of subsidiaries and affiliates' stocks.

Net cash used in operating activities in the six months ended September 30, 2013, was ¥1,887 million, compared with net cash provided by operating activities of ¥1,315 million in the six months ended September 30, 2012. Major factors increasing cash included income before income taxes and minority income and depreciation and amortization. However, these were outweighed by factors decreasing cash such an increase in inventories; decrease in liquor taxes payable, a result of the previous fiscal year-end being a holiday; and income taxes paid.

Net cash used in investing activities amounted to ¥1,989 million, down ¥604 million year on year. Revenues were recorded from the sale of a portion of the stock held in Takara Bio, but outflows came in the form of payments for purchase of property, plant and equipment and stock in subsidiaries as well as payments into time deposits.

Net cash provided by financing activities was ¥4,288 million, up ¥3,151 million year on year. While there were outflows in the forms of redemption of bonds and cash dividends paid, these outflows were offset by the revenues from payments from minority interests following the issuance of new shares by Takara Bio through a public stock offer.

As a result, cash and cash equivalents as of September 30, 2013, stood at ¥36,564 million, up ¥1,276 million from the previous fiscal year-end.

(3) Qualitative Information Regarding Consolidated Forecasts

Full-year consolidated net sales are expected to be ¥209.0 billion, ¥2.7 billion higher than initially forecasted. This is because the Takara Shuzo Group's net sales will likely exceed initial forecasts due to the strong performance of overseas subsidiaries and the influences of yen depreciation, and because the Takara Bio Group is anticipated to record net sales that are higher than forecasted due to the influences of yen depreciation among other factors.

Full-year consolidated operating income and ordinary income are expected to exceed initial forecasts by a slight ¥9.3 billion and ¥9.6 billion respectively. While both figures were higher than anticipated in the six months ended September 30, 2013, the Takara Shuzo Group's domestic alcoholic beverages business is expected to continue experiencing a difficult operating environment during the second half of the fiscal year, limiting income growth.

Full-year net income is projected to be ¥9.7 billion, ¥4.8 billion higher than initially forecasted, due to the recording of gain on sales of subsidiaries and affiliates' stocks.

Revised figures for the business results forecast for the fiscal year ending March 31, 2014 (from April 1, 2013, to March 31, 2014)

(Millions of yen)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecast (A) (May 9, 2013, announcement)	206,300	9,200	9.400	4.900	24.15 yen
Revised forecast (B)	209,000	9,300	9,600	9,700	47.82 yen
Difference (B－A)	2,700	100	200	4,800	－
Difference (%)	1.3	1.1	2.1	98.0	－
Reference: Previous business results (Fiscal year ended March 31, 2013)	200,989	9,133	9,296	4,687	23.01 yen

2. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2013	As of Sep. 30, 2013
Assets		
Current assets		
Cash and deposits	36,789	38,213
Notes and accounts receivable-trade	50,630	50,103
Securities	15,260	23,946
Merchandise and finished goods	21,773	25,287
Work in process	1,090	1,580
Raw materials and supplies	2,841	2,982
Other	4,982	5,051
Allowance for doubtful accounts	(82)	(89)
Total current assets	133,285	147,077
Noncurrent assets		
Property, plant and equipment	42,639	44,056
Intangible assets		
Goodwill	3,767	6,388
Other	1,659	1,794
Total intangible assets	5,426	8,183
Investments and other assets		
Investment securities	21,080	28,521
Other	5,364	5,522
Allowance for doubtful accounts	(209)	(204)
Total investments and other assets	26,235	33,839
Total noncurrent assets	74,301	86,079
Total assets	207,586	233,157
Liabilities		
Current liabilities		
Notes and accounts payable-trade	13,028	13,582
Short-term loans payable	5,006	5,741
Current portion of bonds	5,000	―
Accrued alcohol tax	9,907	7,885
Accrued expenses	4,698	3,955
Income taxes payable	1,996	4,251
Provision for bonuses	1,980	2,327
Other provision	1,753	1,782
Other	6,023	10,410
Total current liabilities	49,394	49,936
Noncurrent liabilities		
Bonds payable	25,000	25,000
Long-term loans payable	417	294
Provision for retirement benefits	8,845	8,693
Long-term deposits received	5,626	5,616
Other	3,983	5,006
Total noncurrent liabilities	43,873	44,611
Total liabilities	93,268	94,547

(Millions of yen)

	As of Mar. 31, 2013	As of Sep. 30, 2013
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,195	3,195
Retained earnings	90,437	101,068
Treasury stock	(8,355)	(8,371)
Total shareholders' equity	98,503	109,118
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	4,599	6,114
Deferred gains or losses on hedges	16	78
Foreign currency translation adjustment	(3,079)	(396)
Total accumulated other comprehensive income	1,537	5,796
Minority interests	14,277	23,694
Total net assets	114,318	138,609
Total liabilities and net assets	207,586	233,157

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Stetements of Comprehensive Income

(Consolidated Quarterly Statements of Income)

(For the Six Months Ended September 30, 2013 and 2012)

(Millions of Yen)

	FY2013_2Q (Apr. 1, 2012 - Sep. 30, 2012)	FY2014_2Q (Apr. 1, 2013 - Sep. 30, 2013)
Net sales	95,711	97,561
Cost of sales	59,163	60,608
Gross profit	36,548	36,953
Selling, general and administrative expenses	33,648	34,558
Operating income	2,899	2,395
Non-operating income		
Dividends income	195	198
Other	258	309
Total non-operating income	453	508
Non-operating expenses		
Interest expenses	278	223
Other	200	115
Total non-operating expenses	478	339
Ordinary income	2,874	2,564
Extraordinary income		
Gain on sales of subsidiaries and affiliates' stocks	—	9,261
Other	133	82
Total extraordinary income	133	9,344
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	111	43
Directors' retirement benefits	—	24
Other	1,289	0
Total extraordinary losses	1,400	68
Income before income taxes and minority interests	1,607	11,839
Income taxes-current	1,163	4,937
Income taxes-deferred	(120)	167
Total income taxes	1,042	5,104
Income before minority interests	564	6,734
Minority interests in income	158	125
Net income	405	6,609

(Consolidated Quarterly Statements of Comprehensive Income)

(For the Six Months Ended September 30, 2013 and 2012)

(Millions of Yen)

	FY2013_2Q (Apr. 1, 2012 - Sep. 30, 2012)	FY2014_2Q (Apr. 1, 2013 - Sep. 30, 2013)
Income before minority interests	564	6,734
Other comprehensive income		
Valuation difference on available-for-sale securities	(657)	1,514
Deferred gains or losses on hedges	(9)	64
Foreign currency translation adjustment	337	3,149
Share of other comprehensive income of associates accounted for using equity method	6	249
Gain or loss on change in equity	—	5,847
Total other comprehensive income	(323)	10,825
Comprehensive income	241	17,559
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	(1)	16,715
Comprehensive income attributable to minority interests	242	844

(3) Consolidated Quarterly Statements of Cash Flows

(Millions of Yen)

	FY2013_2Q (Apr. 1, 2012 - Sep. 30, 2012)	FY2014_2Q (Apr. 1, 2013 - Sep. 30, 2013)
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	1,607	11,839
Depreciation and amortization	2,052	2,028
Interest and dividends income	(281)	(272)
Interest expenses	278	223
Loss (gain) on sales of stocks of subsidiaries and affiliates	—	(9,261)
Decrease (increase) in notes and accounts receivable-trade	279	1,560
Decrease (increase) in inventories	(1,199)	(2,907)
Increase (decrease) in notes and accounts payable-trade	(1,616)	122
Decrease increase in liquor taxes payable	1,069	(2,023)
Other, net	1,451	(773)
Subtotal	3,640	536
Interest and dividends income received	329	311
Interest expenses paid	(245)	(242)
Income taxes paid	(2,410)	(2,493)
Net cash provided by (used in) operating activities	1,315	(1,887)
Net cash provided by (used in) investing activities		
Payments into time deposits	(13,825)	(18,363)
Proceeds from withdrawal of time deposits	14,202	10,935
Purchase of securities	(571)	(1,695)
Proceeds from sales and redemption of securities	612	701
Purchase of property, plant and equipment and intangible assets	(3,021)	(3,085)
Proceeds from sales of stocks of subsidiaries and affiliates	—	12,241
Purchase of investments in subsidiaries resulting in change in scope of consolidation	(48)	(2,666)
Other, net	57	(56)
Net cash provided by (used in) investing activities	(2,594)	(1,989)
Net cash provided by (used in) financing activities		
Proceeds from issuance of bonds	9,923	—
Redemption of bonds	(5,000)	(5,000)
Proceeds from stock issuance to minority shareholders		11,420
Cash dividends paid	(1,847)	(1,823)
Other, net	(1,938)	(308)
Net cash provided by (used in) financing activities	1,137	4,288
Effect of exchange rate change on cash and cash equivalents	79	865
Net increase (decrease) in cash and cash equivalents	(62)	1,276
Cash and cash equivalents at beginning of period	29,165	35,287
Cash and cash equivalents at end of period	29,102	36,564

(4) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2012, to September 30, 2012)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	84,457	8,708	1,133	94,299	1,193	95,492	219	95,711
Intersegment	451	305	2	759	2,424	3,183	(3,183)	-
Total	84,909	9,013	1,135	95,058	3,617	98,676	(2,964)	95,711
Segment income (loss)	2,014	423	(3)	2,434	53	2,488	411	2,899

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥30 million and income of the Company not allocated to business segments of ¥380 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No significant items requiring inclusion.

II. Period under Review (From April 1, 2013, to September 30, 2013)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	85,540	9,986	673	96,200	1,147	97,347	213	97,561
Intersegment	172	290	1	463	2,329	2,793	(2,793)	-
Total	85,712	10,277	674	96,663	3,477	100,141	(2,579)	97,561
Segment income (loss)	1,463	454	(4)	1,913	103	2,017	377	2,395

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥39 million and income of the Company not allocated to business segments of ¥338 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

(Material impairment losses on noncurrent assets)

No items to report.

(Material changes in the amount of goodwill)

In the Takara Shuzo Group segment, goodwill increased ¥2,506 million in the six months ended September 31, 2013, due to factors including the acquisition of stock in newly consolidated T. Tazaki & Company Limited.

平成26年3月期
第2四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Second Quarter Ended September 30, 2013

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
   ① グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)
   ② 要約貸借対照表
   Consolidated Balance Sheets (Summary)

2. 宝酒造グループ
Takara Shuzo Group
   ① 要約損益計算書
   Statements of Income (Summary)
   ② 要約貸借対照表
   Balance Sheets (Summary)

3. タカラバイオグループ
Takara Bio Group
   ① 要約損益計算書
   Statements of Income (Summary)
   ② 要約貸借対照表
   Balance Sheets (Summary)

4. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

5. 平成26年3月期 業績予想
Financial forecast for the year ending March 31, 2014
   ① 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   ② 宝酒造グループ
   Takara Shuzo Group
   ③ タカラバイオグループ
   Takara Bio Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成25年3月期 第2四半期累計	平成26年3月期 第2四半期累計 Apr. 1, 2013 - Sep. 30, 2013		対前期 Change from FY2013(1Q-2Q)		対5/9予想 Difference from forecast announced May 2013	
	実績(a) FY2013(1Q-2Q) Actual (a)	5/9予想(b) FY2014(1Q-2Q) Forecast announced May 2013 (b)	実績(c) FY2014(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	比(c/a) YOY% (c/a)	増減(c-b) Difference (c-b)	比(c/b) % (c/b)
宝酒造 グループ Takara Shuzo Group	84,909	84,800	85,712	802	100.9%	912	101.1%
タカラバイオ グループ Takara Bio Group	9,013	＊ 9,818	10,277	1,263	114.0%	458	104.7%
宝ヘルスケア Takara Healthcare Inc.	1,135	650	674	△ 461	59.4%	24	103.8%
その他 Other, net	653	1,032	897	244	137.4%	△ 134	87.0%
売上高 Net sales	95,711	96,300	97,561	1,849	101.9%	1,261	101.3%
売上原価 Cost of sales	59,163	59,400	60,608	1,444	102.4%	1,208	102.0%
売上総利益 Gross profit	36,548	36,900	36,953	405	101.1%	53	100.1%
運送費、保管料 Transportation and storage	3,528	3,600	3,652	124	103.5%	52	101.5%
広告宣伝費 Advertising	2,088	2,000	2,001	△ 87	95.8%	1	100.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	15,914	16,900	16,131	217	101.4%	△ 768	95.5%
研究開発費 Research and development	1,489	1,500	1,578	88	105.9%	78	105.2%
管理費、その他 Other, net	10,627	10,900	11,193	566	105.3%	293	102.7%
販売費及び一般管理費 SG&A expenses	33,648	34,900	34,558	909	102.7%	△ 341	99.0%
宝酒造 グループ Takara Shuzo Group	2,014	1,050	1,463	△ 550	72.7%	413	139.4%
タカラバイオ グループ Takara Bio Group	423	＊ 427	454	30	107.3%	27	106.4%
宝ヘルスケア Takara Healthcare Inc.	△ 3	△ 14	△ 4	△ 1	—	9	—
その他 Other, net	464	537	481	16	103.6%	△ 55	89.7%
営業利益(△:損失) Operating income(Δ:loss)	2,899	2,000	2,395	△ 504	82.6%	395	119.8%
受取利息・配当金 Interest and Dividends income	281	250	272	△ 9	96.8%	22	108.9%
その他営業外収益 Other, net	172	150	235	63	136.9%	85	157.2%
営業外収益 Non-operating income	453	400	508	54	112.0%	108	127.0%
支払利息 Interest and discounts expenses	278	250	223	△ 54	80.5%	△ 26	89.6%
その他営業外費用 Other, net	200	150	115	△ 84	57.6%	△ 34	76.9%
営業外費用 Non-operating expenses	478	400	339	△ 139	70.9%	△ 60	84.8%
経常利益(△:損失) Ordinary income(Δ:loss)	2,874	2,000	2,564	△ 310	89.2%	564	128.2%
特別利益 Extraordinary gain	133	—	9,344	9,210	6995.5%	9,344	—
特別損失 Extraordinary loss	1,400	100	68	△ 1,332	4.9%	△ 31	68.6%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,607	1,900	11,839	10,232	736.6%	9,939	623.1%
法人税、住民税及び事業税 Current income taxes	1,163	900	4,937	3,774	424.5%	4,204	567.2%
法人税等調整額 Deferred income taxes	△ 120		167	287	—		
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	564	1,000	6,734	6,170	1193.2%	5,734	673.5%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	158	150	125	△ 33	79.0%	△ 24	83.7%
四半期純利益(△:損失) Net income(Δ:loss)	405	850	6,609	6,203	1629.7%	5,759	777.6%
設備投資額(有形・無形) Capital expenditures	2,254		2,808	553	124.6%		
減価償却費(有形・無形) Depreciation and Amortization	2,052	2,000	2,028	△ 23	98.9%	28	101.4%

＊ タカラバイオグループは、平成26年3月期第2四半期累計期間の業績予想を7/30に修正しております。(p7参照)
Takara Bio Group revised FY2014(1Q-2Q) forecasts on Jul. 30, 2013. (c.f. p7.)

営業外収益 Non-operating income	受取利息73、受取配当金198、持分法による投資利益67、為替差益39 など Interest income 73, Dividends income 198, Equity in earnings of affiliates 67, Foreign exchange gains 39, etc.
営業外費用 Non-operating expenses	支払利息75、社債利息148、株式交付費62 など Interest expense 75, Interest on bonds 148, Stock issuance cost 62, etc.
特別利益 Extraordinary gain	関係会社株式売却益9,261 など Gain on sales of subsidiaries and affiliates' stocks 9,261, etc.
特別損失 Extraordinary loss	(前期:投資有価証券評価損1,019、厚生年金基金脱退拠出金260 など) (FY2013(1Q-2Q): Loss on valuation of investment securities 1,019, Contribution for withdrawal from employees pension fund 260, etc.)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets　　（百万円 :Millions of Yen）

	平成25年3月期末 As of Mar. 31, 2013	平成26年3月期第2四半期末 As of Sep. 30, 2013	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	133,285	147,077	13,792	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	36,789	38,213	1,424	TH△33.1、TS△16.1、TB＋66.5
受取手形及び売掛金 Notes and accounts receivable-trade	50,630	50,103	△ 527	TS＋7.6、TB△12.4
有価証券 Marketable securities	15,260	23,946	8,686	TH＋34.9、TS＋5.3、TB＋46.5
たな卸資産 Inventories	25,705	29,851	4,145	TS＋33.0、TB＋8.6
その他 Other current assets	4,982	5,051	69	
貸倒引当金 Allowance for doubtful accounts	△ 82	△ 89	△ 6	
（固定資産） (Total fixed assets)	74,301	86,079	11,778	
〔有形固定資産〕 [Property, plant and equipment]	42,639	44,056	1,417	
建物及び構築物 Buildings and structures	14,182	14,178	△ 4	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	10,192	10,194	2	新規取得　＋28.0　（TS＋9.3、TB＋18.4） Newly purchases +28.0
土地 Land	14,920	14,944	24	減価償却　△20.2　（TS△13.9、TB△5.5） Depreciation Δ20.2
その他 Other property, plant and equipment	3,344	4,738	1,394	その他増減　＋33.9 Other, net +33.9
〔無形固定資産〕 [Intangible fixed assets]	5,426	8,183	2,756	
のれん Goodwill	3,767	6,388	2,621	
その他 Other intangible fixed assets	1,659	1,794	135	
〔投資その他の資産〕 [Investments and other assets]	26,235	33,839	7,604	
投資有価証券 Investment securities	21,080	28,521	7,440	TH時価評価差額＋21.9 TH Valuation difference +21.9
その他 Other assets	5,364	5,522	158	
貸倒引当金 Allowance for doubtful accounts	△ 209	△ 204	4	
資産合計 Total assets	207,586	233,157	25,571	

(TH=Takara Holdings Inc., TS=Takara Shuzo Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets　　（百万円 :Millions of Yen）

	平成25年3月期末 As of Mar. 31, 2013	平成26年3月期第2四半期末 As of Sep. 30, 2013	増減 Change	主な増減理由 Reference
（流動負債） (Total current liabilities)	49,394	49,936	541	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	13,028	13,582	554	TS＋11.0、TB△1.2
短期借入金 Short-term loans payable	5,006	5,741	734	TH＋2.5
1年内償還の社債 Current portion of bonds	5,000	―	△ 5,000	TH△50.0 (#6SB Redemption, May 2013)
未払酒税 Accrued alcohol tax	9,907	7,885	△ 2,022	TS△20.2
未払費用 Accrued expenses	4,698	3,955	△ 743	TS△4.9
販売促進引当金 Reserve for sales promotion expenses	1,719	1,771	51	
その他 Other current liabilities	10,033	17,000	6,966	未払法人税等＋22.5 Accrued income taxes +22.5
（固定負債） (Total non-current liabilities)	43,873	44,611	737	
社債 Bonds payable	25,000	25,000	―	
長期借入金 Long-term loans payable	417	294	△ 123	
退職給付引当金 Reserve for retirement benefits	8,845	8,693	△ 152	
預り金 Deposits from customers	5,626	5,616	△ 9	
その他 Other non-current liabilities	3,983	5,006	1,023	TH繰延税金負債＋10.6 TH Deferred tax liabilities +10.6
負債合計 Total liabilities	93,268	94,547	1,279	
資本金 Capital stock	13,226	13,226	―	
資本剰余金 Capital surplus	3,195	3,195	0	
利益剰余金 Retained earnings	90,437	101,068	10,631	
自己株式 Treasury stock	△ 8,355	△ 8,371	△ 15	
（株主資本） (Total owner's equity)	98,503	109,118	10,615	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	4,599	6,114	1,514	TH＋15.4
繰延ヘッジ損益 Deffered gains or losses on hedges	16	78	61	
為替換算調整勘定 Translation adjustments	△ 3,079	△ 396	2,682	TS＋15.4、TB＋17.1 USD=98.63JPY, EUR=128.56JPY, GBP=150.41JPY (Jun. 2013) USD=86.58JPY, EUR=114.69JPY, GBP=139.53JPY (Dec. 2012)
（その他の包括利益累計額） (Total valuation and translation adjustments)	1,537	5,796	4,258	
（少数株主持分） (Minority interests)	14,277	23,694	9,417	
純資産合計 Total net assets	114,318	138,609	24,291	
負債純資産合計 Total liabilities and net assets	207,586	233,157	25,571	

(TH=Takara Holdings Inc., TS=Takara Shuzo Group, TB=Takara Bio Group)

2. 宝酒造グループ :Takara Shuzo Group

① 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成25年3月期 第2四半期累計	平成26年3月期 第2四半期累計 Apr. 1, 2013 - Sep. 30, 2013		対前期 Change from FY2013(1Q-2Q)		対5/9予想 Difference from forecast announced May 2013	
	実績(a) FY2013(1Q-2Q) Actual (a)	5/9予想(b) FY2014(1Q-2Q) Forecast announced May 2013 (b)	実績(c) FY2014(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	比(c/a) YOY% (c/a)	増減(c-b) Difference (c-b)	比(c/b) % (c/b)
焼酎 Shochu	35,886	32,600	33,128	△ 2,757	92.3%	528	101.6%
清酒 Sake	7,903	8,300	8,368	464	105.9%	68	100.8%
ソフトアルコール飲料 Light-alcohol refreshers	13,394	16,700	14,467	1,073	108.0%	△ 2,232	86.6%
その他酒類 Other liquors	5,415	5,100	5,986	571	110.5%	886	117.4%
本みりん Hon Mirin	6,928	6,700	6,811	△ 116	98.3%	111	101.7%
その他調味料 Other seasonings	3,676	3,800	3,940	263	107.2%	140	103.7%
原料用アルコール等 Raw alcohol	3,223	3,200	3,184	△ 39	98.8%	△ 15	99.5%
その他 Other	8,480	8,400	9,824	1,344	115.9%	1,424	117.0%
売上高 Net sales	84,909	84,800	85,712	802	100.9%	912	101.1%
売上原価 Cost of sales	54,287	53,900	55,239	951	101.8%	1,339	102.5%
売上総利益 Gross profit	30,622	30,900	30,473	△ 149	99.5%	△ 426	98.6%
運送費、保管料 Transportation and storage	3,187	3,350	3,343	156	104.9%	△ 6	99.8%
広告宣伝費 Advertising	1,934	1,800	1,782	△ 152	92.1%	△ 17	99.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	15,450	16,350	15,600	149	101.0%	△ 749	95.4%
研究開発費 Research and development	179	200	166	△ 13	92.3%	△ 33	83.0%
管理費、その他 Other, net	7,856	8,150	8,116	260	103.3%	△ 33	99.6%
販売費及び一般管理費 SG&A expenses	28,608	29,850	29,009	401	101.4%	△ 840	97.2%
営業利益（△：損失） Operating income(Δ:loss)	2,014	1,050	1,463	△ 550	72.7%	413	139.4%
営業外収益 Non-operating income	209	200	234	24	111.6%	34	117.0%
営業外費用 Non-operating expenses	122	150	99	△ 23	80.9%	△ 50	66.3%
経常利益（△：損失） Ordinary income(Δ:loss)	2,101	1,100	1,598	△ 502	76.1%	498	145.3%
特別利益 Extraordinary gain	25	—	8	△ 17	33.8%	8	—
特別損失 Extraordinary loss	319	70	39	△ 279	12.4%	△ 30	56.4%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	1,807	1,030	1,567	△ 239	86.7%	537	152.2%
法人税、住民税及び事業税 Current income taxes	823	550	817	△ 5	99.3%	231	142.1%
法人税等調整額 Deferred income taxes	19		△ 35	△ 55	—		
少数株主損益調整前四半期純利益（△：損失） Income(Δ:loss) before minority interests	964	480	786	△ 178	81.5%	306	163.8%
少数株主利益（△：損失） Minority interests in net income(Δ:loss)	69	50	64	△ 5	92.6%	14	128.3%
四半期純利益（△：損失） Net income(Δ:loss)	895	430	721	△ 173	80.6%	291	167.9%
設備投資額（有形・無形） Capital expenditures	1,220		930	△ 290	76.2%		
減価償却費（有形・無形） Depreciation and Amortization	1,444	1,500	1,397	△ 47	96.7%	△ 102	93.1%

*平成25年3月期の実績において、「ソフトアルコール飲料」の一部を「焼酎」に、「その他」の一部を「その他酒類」にそれぞれ組替えております。
（平成26年3月期の区分に合わせております。）

② 要約貸借対照表 :Balance Sheets (Summary)

資産の部 :Assets

（百万円 :Millions of Yen）

	平成25年3月期末 As of Mar. 31, 2013	平成26年3月期第2四半期末 As of Sep. 30, 2013	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	86,215	88,998	2,783	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	10,888	9,277	△ 1,610	米国宝ホールディング△16.9 USA Takara Holding Δ16.9
受取手形及び売掛金 Notes and accounts receivable-trade	44,150	44,917	767	フーデックス＋3.4、タザキフーズ＋5.6 Foodex +3.4, Tazaki Foods +5.6
有価証券 Marketable securities	4,241	4,778	536	
たな卸資産 Inventories	22,107	25,413	3,305	宝酒造＋13.5、ラック・コーポレーション＋4.3、トマーチン＋4.4、タザキフーズ＋4.6 Takara Shuzo +13.5, Luc Corporation +4.3, The Tomatin Disillery +4.4, Tazaki Foods +4.6
その他 Other current assets	4,874	4,672	△ 201	
貸倒引当金 Allowance for doubtful accounts	△ 46	△ 60	△ 13	
（固定資産） (Total fixed assets)	38,417	41,169	2,751	
〔有形固定資産〕 [Property, plant and equipment]	26,682	26,593	△ 89	
建物及び構築物 Buildings and structures	9,653	9,571	△ 82	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	8,739	8,652	△ 86	新規取得 ＋9.3 Newly purchases +9.3
土地 Land	6,910	6,914	4	減価償却 △13.9 Depreciation Δ13.9
その他 Other property, plant and equipment	1,379	1,454	74	その他増減 ＋28.6 Other, net +28.6
〔無形固定資産〕 [Intangible fixed assets]	3,247	5,732	2,484	
のれん Goodwill	2,435	4,942	2,506	
その他 Other intangible fixed assets	811	790	△ 21	
〔投資その他の資産〕 [Investments and other assets]	8,487	8,843	356	
投資有価証券 Investment securities	4,761	5,011	249	
その他 Other assets	3,827	3,932	104	
貸倒引当金 Allowance for doubtful accounts	△ 101	△ 100	1	
資産合計 Total assets	124,633	130,167	5,534	

② 要約貸借対照表 :Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets

（百万円 :Millions of Yen）

	平成25年3月期末 As of Mar. 31, 2013	平成26年3月期第2四半期末 As of Sep. 30, 2013	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	34,586	37,611	3,025	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	10,194	11,303	1,109	宝酒造＋7.4、フーデックス＋1.5、タザキフーズ＋2.4 Takara Shuzo +7.4, Foodex +1.5, Tazaki Foods +2.4
短期借入金 Short-term loans payable	902	6,708	5,805	宝酒造＋50.0、ラック・コーポレーション＋2.6、タザキフーズ＋4.3 Takara Shuzo +50.5, Luc Corporation +2.6, Tazaki Foods+4.3
未払酒税 Accrued alcohol tax	9,907	7,885	△ 2,022	宝酒造△20.2 Takara Shuzo Δ20.2
未払費用 Accrued expenses	4,119	3,628	△ 490	宝酒造△5.5 Takara Shuzo Δ5.5
販売促進引当金 Reserve for sales promotion expenses	1,719	1,771	51	
その他 Other current liabilities	7,742	6,314	△ 1,428	未払法人税等△9.7 Accrued income taxes Δ9.7
(固定負債) (Total non-current liabilities)	16,199	16,149	△ 50	
長期借入金 Long-term loans payable	1,475	1,615	140	
退職給付引当金 Reserve for retirement benefits	8,084	7,965	△ 119	
預り金 Deposits from customers	5,519	5,509	△ 9	
その他 Other non-current liabilities	1,120	1,058	△ 62	
負債合計 Total liabilities	50,786	53,760	2,974	
資本金 Capital stock	1,000	1,000	－	
資本剰余金 Capital surplus	56,678	56,678	－	
利益剰余金 Retained earnings	16,393	17,115	721	
(株主資本) (Total owner's equity)	74,071	74,793	721	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	195	156	△ 39	
繰延ヘッジ損益 Deffered gains or losses on hedges	16	78	61	
為替換算調整勘定 Translation adjustments	△ 2,435	△ 885	1,549	Translation Rate USD=98.63JPY, EUR=128.56JPY, GBP=150.41JPY (Jun. 2013) USD=86.58JPY, EUR=114.69JPY, GBP=139.53JPY (Dec. 2012)
(その他の包括利益累計額) (Total valuation and translation adjustments)	△ 2,222	△ 651	1,570	
(少数株主持分) (Minority interests)	1,997	2,265	267	
純資産合計 Total net assets	73,846	76,406	2,560	
負債純資産合計 Total liabilities and net assets	124,633	130,167	5,534	

3. タカラバイオグループ :Takara Bio Group

① 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成25年3月期 第2四半期累計	平成26年3月期 第2四半期累計 Apr. 1, 2013 - Sep. 30, 2013		対前期 Change from FY2013(1Q-2Q)		対7/30予想 Difference from forecast announced Jul. 2013	
	実績(a) FY2013(1Q-2Q) Actual (a)	7/30予想(b) FY2014(1Q-2Q) Forecast announced Jul. 2013 (b)	実績(c) FY2014(1Q-2Q) Actual (c)	増減(c−a) Change (c-a)	比(c/a) YOY% (c/a)	増減(c−b) Difference (c-b)	比(c/b) % (c/b)
研究用試薬 Research reagents	5,580	6,652	6,620	1,039	118.6%	△ 31	99.5%
理化学機器 Scientific instruments	955	1,012	1,061	106	111.1%	49	104.9%
受託・その他ファイン Contracted service and other	836	981	966	130	115.6%	△ 15	98.5%
遺伝子工学研究　計 Genetic engineering research segment	7,371	8,645	8,648	1,276	117.3%	2	100.0%
遺伝子医療 Gene medicine segment	601	696	695	94	115.7%	△ 0	99.9%
医食品バイオ Agribio segment	1,040	957	933	△ 107	89.7%	△ 24	97.4%
売上高 Net sales	9,013	10,300	10,277	1,263	114.0%	△ 22	99.8%
売上原価 Cost of sales	3,961	4,771	4,673	712	118.0%	△ 97	98.0%
売上総利益 Gross profit	5,052	5,528	5,603	551	110.9%	74	101.4%
運送費、保管料 Transportation and storage	235	236	256	21	108.9%	20	108.7%
広告宣伝費 Advertising	35	66	69	33	194.3%	2	104.4%
販売促進費 Sales promotion	440	497	497	57	113.1%	0	100.2%
研究開発費 Research and development	1,310	1,502	1,407	97	107.4%	△ 95	93.7%
管理費、その他 Other, net	2,606	2,926	2,917	311	111.9%	△ 8	99.7%
販売費及び一般管理費 SG&A expenses	4,628	5,228	5,148	520	111.2%	△ 79	98.5%
遺伝子工学研究 Genetic engineering research segment	2,034	1,959	2,064	29	101.5%	104	105.3%
遺伝子医療 Gene medicine segment	△ 546	△ 664	△ 598	△ 51	—	65	—
医食品バイオ Agribio segment	△ 181	△ 174	△ 188	△ 7	—	△ 13	—
共通 Eliminations/Corporate	△ 882	△ 820	△ 822	60	—	△ 1	—
営業利益(△:損失) Operating income(Δ:loss)	423	300	454	30	107.3%	154	151.4%
営業外収益 Non-operating income	89	109	113	24	127.1%	4	104.2%
営業外費用 Non-operating expenses	59	99	74	14	125.1%	△ 24	75.0%
経常利益(△:損失) Ordinary income(Δ:loss)	453	310	493	40	108.8%	183	159.3%
特別利益 Extraordinary gain	0	0	0	△ 0	55.6%	△ 0	82.9%
特別損失 Extraordinary loss	12	26	26	14	219.7%	0	102.2%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	442	284	467	25	105.7%	183	164.4%
法人税、住民税及び事業税 Current income taxes	322	158	402	79	124.7%	86	154.6%
法人税等調整額 Deferred income taxes	△ 193		△ 157	35	—		
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	312	125	222	△ 90	71.2%	96	176.7%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 1	△ 4	△ 5	△ 3	—	△ 1	—
四半期純利益(△:損失) Net income(Δ:loss)	314	130	227	△ 86	72.4%	97	175.0%
設備投資額(有形・無形) Capital expenditures	765		1,846	1,080	241.1%		
減価償却費(有形・無形) Depreciation and Amortization	536	567	552	16	103.0%	△ 14	97.5%

② 要約貸借対照表 :Balance Sheets (Summary)

資産の部 :Assets

（百万円 :Millions of Yen）

	平成25年3月期末 As of Mar. 31, 2013	平成26年3月期第2四半期末 As of Sep. 30, 2013	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	31,138	42,417	11,279	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	18,267	24,918	6,651	タカラバイオ＋69.1 Takara Bio +69.1
受取手形及び売掛金 Notes and accounts receivable-trade	5,985	4,737	△ 1,248	タカラバイオ△17.8 Takara Bio Δ17.8
有価証券 Marketable securities	2,518	7,168	4,650	タカラバイオ＋45.0 Takara Bio +45.0
たな卸資産 Inventories	3,467	4,329	861	タカラバイオ＋4.7、宝生物工程（大連）＋1.8 Takara Bio +4.7, Takara Biotechnology (Dalian) +1.8
その他 Other current assets	933	1,290	356	繰延税金資産＋2.2 Deferred tax assets +2.2
貸倒引当金 Allowance for doubtful accounts	△ 34	△ 27	6	
（固定資産） (Total fixed assets)	15,510	22,385	6,874	
〔有形固定資産〕 [Property, plant and equipment]	12,196	13,749	1,552	
建物及び構築物 Buildings and structures	3,682	3,780	97	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	1,338	1,427	88	新規取得 ＋18.4 Newly purchases +18.4
土地 Land	5,618	5,639	20	減価償却 △5.5 Depreciation Δ5.5
その他 Other property, plant and equipment	1,557	2,902	1,345	その他増減 ＋5.3 Other, net +5.3
〔無形固定資産〕 [Intangible fixed assets]	2,135	2,411	275	
のれん Goodwill	1,331	1,446	115	
その他 Other intangible fixed assets	804	964	160	
〔投資その他の資産〕 [Investments and other assets]	1,178	6,224	5,046	
長期前払費用 Long-term prepaid expenses	947	978	31	
その他 Other assets	230	5,246	5,015	
貸倒引当金 Allowance for doubtful accounts	－	－	－	
資産合計 Total assets	46,649	64,803	18,153	

② 要約貸借対照表 :Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets　　（百万円 :Millions of Yen）

	平成25年3月期末 As of Mar. 31, 2013	平成26年3月期第2四半期末 As of Sep. 30, 2013	増減 Change	主な増減理由 Reference
（流動負債） (Total current liabilities)	3,977	8,810	4,833	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	1,605	1,479	△ 126	タカラバイオ△2.7 Takara Bio Δ2.7
短期借入金 Short-term loans payable	83	74	△ 8	
その他 Other current liabilities	2,288	7,257	4,969	未払金＋49.0 Accounts payable-other +49.0
（固定負債） (Total non-current liabilities)	1,206	1,229	22	
長期借入金 Long-term loans payable	273	258	△ 14	
退職給付引当金 Reserve for retirement benefits	416	413	△ 3	
その他 Other non-current liabilities	516	557	40	
負債合計 Total liabilities	5,183	10,040	4,856	
資本金 Capital stock	9,233	14,965	5,732	
資本剰余金 Capital surplus	27,160	32,893	5,732	
利益剰余金 Retained earnings	5,934	6,037	102	
自己株式 Treasury stock	－	－	－	
（株主資本） (Total owner's equity)	42,329	53,897	11,568	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	－	－	－	
為替換算調整勘定 Translation adjustments	△ 914	803	1,717	Translation Rate USD=98.63JPY, EUR=128.56JPY, CNY=16.07JPY (Jun. 2013) USD=86.58JPY, EUR=114.69JPY, CNY=13.91JPY (Dec. 2012)
（その他の包括利益累計額） (Total valuation and translation adjustments)	△ 914	803	1,717	
（少数株主持分） (Minority interests)	50	62	12	
純資産合計 Total net assets	41,465	54,762	13,297	
負債純資産合計 Total liabilities and net assets	46,649	64,803	18,153	

4. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

		平成21年3月期 第2四半期累計 FY2009(1Q-2Q)	平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	前期対比 Change from FY2013(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	91,978	91,125	91,472	95,478	95,711	97,561	1,849	101.9%
売上原価	Cost of sales	57,377	56,205	56,068	58,583	59,163	60,608	1,444	102.4%
(売上高原価率)	(Ratio to Net sales)	62.4%	61.7%	61.3%	61.4%	61.8%	62.1%	+0.3pt	—
売上総利益	Gross profit	34,600	34,919	35,404	36,895	36,548	36,953	405	101.1%
販売費及び一般管理費	SG&A expenses	31,851	31,982	32,155	33,569	33,648	34,558	909	102.7%
(売上高販管費率)	(Ratio to Net sales)	34.6%	35.1%	35.2%	35.2%	35.2%	35.4%	+0.3pt	—
営業利益(△:損失)	Operating income(Δ:loss)	2,749	2,937	3,248	3,326	2,899	2,395	Δ 504	82.6%
(売上高営業利益率)	(Ratio to Net Sales)	3.0%	3.2%	3.6%	3.5%	3.0%	2.5%	-0.6pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	14,312	14,660	14,872	15,551	15,914	16,131	217	101.4%
(売上高販促費率)	(Ratio to Net sales)	15.6%	16.1%	16.3%	16.3%	16.6%	16.5%	-0.1pt	—
研究開発費	R&D expenses	1,603	1,684	1,424	1,440	1,489	1,578	88	105.9%
(売上高研究開発費率)	(Ratio to Net sales)	1.7%	1.8%	1.6%	1.5%	1.6%	1.6%	+0.1pt	—
設備投資額(有形・無形)	Capital expenditures	1,691	1,640	1,515	2,746	2,254	2,808	553	124.6%
減価償却費(有形・無形)	Depreciation and Amortization	2,481	2,374	2,200	2,151	2,052	2,028	Δ 23	98.9%

宝酒造グループ :Takara Shuzo Group

(百万円 :Millions of Yen)

		平成21年3月期 第2四半期累計 FY2009(1Q-2Q)	平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	前期対比 Change from FY2013(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	80,637	80,153	80,754	84,996	84,909	85,712	802	100.9%
売上原価	Cost of sales	51,628	50,732	50,771	53,752	54,287	55,239	951	101.8%
(売上高原価率)	(Ratio to Net sales)	64.0%	63.3%	62.9%	63.2%	63.9%	64.4%	+0.5pt	—
売上総利益	Gross profit	29,008	29,420	29,982	31,244	30,622	30,473	Δ 149	99.5%
販売費及び一般管理費	SG&A expenses	26,537	26,882	27,198	28,674	28,608	29,009	401	101.4%
(売上高販管費率)	(Ratio to Net sales)	32.9%	33.5%	33.7%	33.7%	33.7%	33.8%	+0.2pt	—
営業利益(△:損失)	Operating income(Δ:loss)	2,471	2,537	2,784	2,569	2,014	1,463	Δ 550	72.7%
(売上高営業利益率)	(Ratio to Net sales)	3.1%	3.2%	3.4%	3.0%	2.4%	1.7%	-0.7pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	13,617	14,078	14,409	15,083	15,450	15,600	149	101.0%
(売上高販促費率)	(Ratio to Net sales)	16.9%	17.6%	17.8%	17.7%	18.2%	18.2%	+0.0pt	—
設備投資額(有形・無形)	Capital expenditures	1,015	1,164	1,060	1,081	1,220	930	Δ 290	76.2%
減価償却費(有形・無形)	Depreciation and Amortization	1,751	1,676	1,565	1,550	1,444	1,397	Δ 47	96.7%

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

		平成21年3月期 第2四半期累計 FY2009(1Q-2Q)	平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	前期対比 Change from FY2013(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	8,927	8,690	8,443	8,642	9,013	10,277	1,263	114.0%
売上原価	Cost of sales	4,309	4,110	3,960	3,873	3,961	4,673	712	118.0%
(売上高原価率)	(Ratio to Net sales)	48.3%	47.3%	46.9%	44.8%	43.9%	45.5%	+1.5pt	—
売上総利益	Gross profit	4,618	4,580	4,483	4,768	5,052	5,603	551	110.9%
販売費及び一般管理費	SG&A expenses	4,744	4,589	4,288	4,374	4,628	5,148	520	111.2%
(売上高販管費率)	(Ratio to Net sales)	53.1%	52.8%	50.8%	50.6%	51.4%	50.1%	-1.3pt	—
営業利益(△:損失)	Operating income(Δ:loss)	Δ 125	Δ 9	194	394	423	454	30	107.3%
(売上高営業利益率)	(Ratio to Net sales)	—	—	2.3%	4.6%	4.7%	4.4%	-0.3pt	—
研究開発費	R&D expenses	1,430	1,502	1,240	1,258	1,310	1,407	97	107.4%
(売上高研究開発費率)	(Ratio to Net sales)	16.0%	17.3%	14.7%	14.6%	14.5%	13.7%	-0.8pt	—
設備投資額(有形・無形)	Capital expenditures	593	448	402	403	765	1,846	1,080	241.1%
減価償却費(有形・無形)	Depreciation and Amortization	664	626	562	532	536	552	16	103.0%

宝ヘルスケア :Takara Healthcare Inc.

(百万円 :Millions of Yen)

		平成21年3月期 第2四半期累計 FY2009(1Q-2Q)	平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	前期対比 Change from FY2013(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	1,765	1,544	1,516	1,326	1,135	674	Δ 461	59.4%
売上原価	Cost of sales	1,336	1,146	1,062	879	732	318	Δ 413	43.5%
(売上高原価率)	(Ratio to Net sales)	75.7%	74.2%	70.1%	66.3%	64.5%	47.2%	-17.2pt	—
売上総利益	Gross profit	429	398	453	447	403	356	Δ 47	88.2%
販売費及び一般管理費	SG&A expenses	599	564	569	533	406	360	Δ 46	88.6%
(売上高販管費率)	(Ratio to Net sales)	34.0%	36.6%	37.5%	40.2%	35.8%	53.4%	+17.6pt	—
営業利益(△:損失)	Operating income(Δ:loss)	Δ 170	Δ 166	Δ 115	Δ 86	Δ 3	Δ 4	Δ 1	—
(売上高営業利益率)	(Ratio to Net sales)	—	—	—	—	—	—	—	—
ヘルスケア事業売上高	Net sales of Healthcare products	369	384	530	580	608	674	65	110.8%
設備投資額(有形・無形)	Capital expenditures	—	—	—	26	0	1	0	184.4%
減価償却費(有形・無形)	Depreciation and Amortization	5	4	5	5	5	0	Δ 5	2.0%

5. 平成26年3月期 業績予想 :Financial forecast for the year ending March 31, 2014

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	平成25年3月期 FY2013	平成26年3月期 FY2014_Apr. 1, 2013 - Mar. 31, 2014		対前期 Change from FY2013		対5/9予想 Change from forecast announced May 2013	
	実績(a) Actual (a)	5/9予想(b) Forecast announced May 2013 (b)	11/1予想(c) Forecast announced Nov. 2013 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
宝酒造 グループ Takara Shuzo Group	176,946	180,900	182,100	5,153	102.9%	1,200	100.7%
タカラバイオ グループ Takara Bio Group	20,564	22,100	23,700	3,135	115.2%	1,600	107.2%
宝ヘルスケア Takara Healthcare Inc.	2,008	1,350	1,350	△ 658	67.2%	—	100.0%
その他 Other, net	1,469	1,950	1,850	380	125.9%	△ 100	94.9%
売上高 Net sales	200,989	206,300	209,000	8,010	104.0%	2,700	101.3%
売上原価 Cost of sales	123,630	125,500	128,500	4,869	103.9%	3,000	102.4%
売上総利益 Gross profit	77,359	80,800	80,500	3,140	104.1%	△ 300	99.6%
運送費、保管料 Transportation and storage	7,324	7,600	7,700	375	105.1%	100	101.3%
広告宣伝費 Advertising	3,797	3,900	3,500	△ 297	92.2%	△ 400	89.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,838	34,500	33,400	561	101.7%	△ 1,100	96.8%
研究開発費 Research and development	3,090	3,700	3,700	609	119.7%	—	100.0%
管理費、その他 Other, net	21,174	21,900	22,900	1,725	108.1%	1,000	104.6%
販売費及び一般管理費 SG&A expenses	68,225	71,600	71,200	2,974	104.4%	△ 400	99.4%
宝酒造 グループ Takara Shuzo Group	6,387	6,200	6,200	△ 187	97.1%	—	100.0%
タカラバイオ グループ Takara Bio Group	1,691	1,750	1,900	208	112.3%	150	108.6%
宝ヘルスケア Takara Healthcare Inc.	△ 22	6	8	30	—	2	133.3%
その他 Other,net	1,076	1,244	1,192	115	110.7%	△ 52	95.8%
営業利益(△:損失) Operating income(Δ:loss)	9,133	9,200	9,300	166	101.8%	100	101.1%
受取利息・配当金 Interest and Dividends income	536	500	500	△ 36	93.3%	—	100.0%
その他営業外収益 Other, net	488	400	500	11	102.3%	100	125.0%
営業外収益 Non-operating income	1,025	900	1,000	△ 25	97.6%	100	111.1%
支払利息 Interest and discounts expenses	523	500	500	△ 23	95.5%	—	100.0%
その他営業外費用 Other, net	338	200	200	△ 138	59.1%	—	100.0%
営業外費用 Non-operating expenses	862	700	700	△ 162	81.2%	—	100.0%
経常利益(△:損失) Ordinary income(Δ:loss)	9,296	9,400	9,600	303	103.3%	200	102.1%
特別利益 Extraordinary gain	1,948	—	9,400	7,451	482.4%	9,400	—
特別損失 Extraordinary loss	1,989	200	1,200	△ 789	60.3%	1,000	600.0%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	9,256	9,200	17,800	8,543	192.3%	8,600	193.5%
法人税、住民税及び事業税 Current income taxes	3,390	3,800	7,600	3,591	189.6%	3,800	200.0%
法人税等調整額 Deferred income taxes	618						
少数株主損益調整前当期純利益(△:損失) Income(Δ:loss) before minority interests	5,247	5,400	10,200	4,952	194.4%	4,800	188.9%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	560	500	500	△ 60	89.2%	—	100.0%
当期純利益(△:損失) Net income(Δ:loss)	4,687	4,900	9,700	5,012	206.9%	4,800	198.0%
設備投資額(有形・無形) Capital expenditures	5,282	9,188	9,188	3,906	173.9%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	4,251	4,100	4,000	△ 251	94.1%	△ 100	97.6%

② 宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

	平成25年3月期 FY2013	平成26年3月期 FY2014_Apr. 1, 2013 - Mar. 31, 2014		対前期 Change from FY2013		対5/9予想 Change from forecast announced May 2013	
	実績(a) Actual (a)	5/9予想(b) Forecast announced May 2013 (b)	11/1予想(c) Forecast announced Nov. 2013 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
焼酎 Shochu	70,630	67,200	66,700	△ 3,930	94.4%	△ 500	99.3%
清酒 Sake	21,737	23,500	24,000	2,262	110.4%	500	102.1%
ソフトアルコール飲料 Light-alcohol refreshers	25,757	31,300	27,600	1,842	107.2%	△ 3,700	88.2%
その他酒類 Other liquors	11,047	10,500	11,900	852	107.7%	1,400	113.3%
本みりん Hon Mirin	14,553	14,400	14,500	△ 53	99.6%	100	100.7%
その他調味料 Other seasonings	7,830	8,100	8,500	669	108.5%	400	104.9%
原料用アルコール等 Raw alcohol	6,922	7,200	6,800	△ 122	98.2%	△ 400	94.4%
その他 Other	18,468	18,700	22,100	3,631	119.7%	3,400	118.2%
売上高 Net sales	176,946	180,900	182,100	5,153	102.9%	1,200	100.7%
売上原価 Cost of sales	112,384	113,700	115,900	3,515	103.1%	2,200	101.9%
売上総利益 Gross profit	64,562	67,200	66,200	1,637	102.5%	△ 1,000	98.5%
運送費、保管料 Transportation and storage	6,668	7,100	7,100	431	106.5%	—	100.0%
広告宣伝費 Advertising	3,420	3,500	3,100	△ 320	90.6%	△ 400	88.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	31,815	33,500	32,400	584	101.8%	△ 1,100	96.7%
研究開発費 Research and development	363	400	400	36	110.0%	—	100.0%
管理費、その他 Other, net	15,906	16,500	17,000	1,093	106.9%	500	103.0%
販売費及び一般管理費 SG&A expenses	58,174	61,000	60,000	1,825	103.1%	△ 1,000	98.4%
営業利益(△:損失) Operating income(Δ:loss)	6,387	6,200	6,200	△ 187	97.1%	—	100.0%
営業外収益 Non-operating income	472	350	400	△ 72	84.7%	50	114.3%
営業外費用 Non-operating expenses	328	250	200	△ 128	60.8%	△ 50	80.0%
経常利益(△:損失) Ordinary income(Δ:loss)	6,531	6,300	6,400	△ 131	98.0%	100	101.6%
特別利益 Extraordinary gain	172	—	10	△ 162	5.8%	10	—
特別損失 Extraordinary loss	596	150	460	△ 136	77.2%	310	306.7%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	6,107	6,150	5,950	△ 157	97.4%	△ 200	96.7%
法人税、住民税及び事業税 Current income taxes	2,510	2,700	2,700	112	104.4%	—	100.0%
法人税等調整額 Deferred income taxes	77						
少数株主損益調整前当期純利益(△:損失) Income(Δ:loss) before minority interests	3,520	3,450	3,250	△ 270	92.3%	△ 200	94.2%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	139	100	150	10	107.7%	50	150.0%
当期純利益(△:損失) Net income(Δ:loss)	3,381	3,350	3,100	△ 281	91.7%	△ 250	92.5%
設備投資額(有形・無形) Capital expenditures	2,529	2,293	2,293	△ 235	90.7%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	2,997	3,000	2,900	△ 97	96.8%	△ 100	96.7%

*平成25年3月期の実績において、「ソフトアルコール飲料」の一部を「焼酎」に、「その他」の一部を「その他酒類」にそれぞれ組替えております。
（平成26年3月期の区分に合わせております。）

③ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	平成25年3月期 FY2013	平成26年3月期 FY2014_Apr. 1, 2013 - Mar. 31, 2014		対前期 Change from FY2013		対5/9予想 Change from forecast announced May 2013	
	実績(a) Actual (a)	5/9予想(b) Forecast announced May 2013 (b)	11/1予想(c) Forecast announced Nov. 2013 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
研究用試薬 Research reagents	12,096	13,695	14,609	2,512	120.8%	913	106.7%
理化学機器 Scientific instruments	2,535	2,260	2,548	13	100.5%	288	112.8%
受託・その他ファイン Contracted service and other	2,365	2,384	2,628	262	111.1%	243	110.2%
遺伝子工学研究　計 Genetic engineering research segment	16,997	18,340	19,786	2,788	116.4%	1,445	107.9%
遺伝子医療 Gene medicine segment	1,240	1,434	1,554	313	125.3%	119	108.3%
医食品バイオ Agribio segment	2,326	2,325	2,360	33	101.4%	34	101.5%
売上高 Net sales	20,564	22,100	23,700	3,135	115.2%	1,600	107.2%
売上原価 Cost of sales	9,540	10,221	11,073	1,532	116.1%	851	108.3%
売上総利益 Gross profit	11,024	11,878	12,627	1,602	114.5%	748	106.3%
運送費、保管料 Transportation and storage	476	419	526	49	110.4%	107	125.7%
広告宣伝費 Advertising	89	97	120	30	134.3%	23	124.2%
販売促進費 Sales promotion	963	920	929	△ 34	96.4%	8	100.9%
研究開発費 Research and development	2,715	3,258	3,243	527	119.4%	△ 14	99.6%
管理費、その他 Other, net	5,086	5,433	5,906	820	116.1%	473	108.7%
販売費及び一般管理費 SG&A expenses	9,332	10,128	10,726	1,394	114.9%	598	105.9%
遺伝子工学研究 Genetic engineering research segment	4,831	4,971	5,056	224	104.7%	85	101.7%
遺伝子医療 Gene medicine segment	△ 1,112	△ 1,424	△ 1,375	△ 262	—	49	—
医食品バイオ Agribio segment	△ 304	△ 219	△ 146	158	—	72	—
共通 Eliminations/Corporate	△ 1,722	△ 1,577	△ 1,633	88	—	△ 56	—
営業利益(△:損失) Operating income(Δ:loss)	1,691	1,750	1,900	208	112.3%	150	108.6%
営業外収益 Non-operating income	322	304	343	20	106.2%	38	112.8%
営業外費用 Non-operating expenses	49	53	93	43	189.1%	39	172.9%
経常利益(△:損失) Ordinary income(Δ:loss)	1,965	2,000	2,150	184	109.4%	150	107.5%
特別利益 Extraordinary gain	348	—	0	△ 348	0.1%	0	—
特別損失 Extraordinary loss	44	27	60	15	133.5%	32	220.8%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	2,268	1,972	2,090	△ 178	92.1%	117	106.0%
法人税、住民税及び事業税 Current income taxes	587	665	741	△ 68	91.6%	75	111.3%
法人税等調整額 Deferred income taxes	222						
少数株主損益調整前当期純利益(△:損失) Income(Δ:loss) before minority interests	1,459	1,307	1,349	△ 110	92.4%	42	103.2%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 3	6	△ 0	2	—	△ 7	—
当期純利益(△:損失) Net income(Δ:loss)	1,462	1,300	1,350	△ 112	92.3%	50	103.8%
設備投資額(有形・無形) Capital expenditures	2,397	6,237	6,237	3,839	260.1%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	1,104	1,127	1,139	34	103.2%	12	101.1%